个人简介

潘婷博士，2014年博士毕业于中山大学中山医学院微生物学专业。曾先后获得广州市“珠江科技新星”（2018年）和深圳市高层次人才（2021年）项目支持。自2019年11月起加入中山大学医学院，任职至今。长期致力于HIV-1的分子生物学与免疫学研究，以及抗病毒药物的开发。近年来，共发表SCI收录学术论文55篇，其中（共同）第一/通讯作者论文18篇。先后主持包括国家新发突发和传染病防控重大专项（任务级2项）、“十三五”科技重大专项“艾滋病和病毒性肝炎等重大传染病防治”项目（子课题级1项、任务级1项）、国家自然科学基金项目3项、广东省自然科学基金项目2项、深圳市重点项目1项及面上项目等多项课题。获中国发明专利授权17项，美国发明专利授权1项。

研究方向：感染免疫

  1. 艾滋病潜伏感染激活剂的研发及功能性治愈策略研究
  2. 抗病毒药物筛选（涵盖艾滋病病毒、新冠病毒、乙肝病毒等）
  3. 慢性病毒感染过程中T细胞的免疫应答机制

承担的科研项目（在研）

(1) 国家自然科学基金委员会, 面上项目, 82472268,在研, 主持 

(2) 国家新发突发与重大传染病防控, 2025ZD01905304, 在研, 骨干

(3) 国家新发突发与传染病防控国家科技重大专项, 2025ZD01904304,在研, 骨干

(4) 深圳市科技创新局基础研究面上项目, JCYJ20240813151256072,在研, 主持

招生招聘

本课题组长期招收博士研究生、硕士研究生、博士后及科研助理岗位。我们将提供具有竞争力的薪酬待遇与良好的职业发展平台，欢迎加入！招生学科专业：071000 生物学，086000 生物与医药。

学科专业

病原生物学、分子生物学、免疫学、生物信息学。

联系方式

Pant8@mail.sysu.edu.cn

部分代表性论文

  1. Deng, X.#, Xie, S.#, Zhou, M.#, Yuan, Q.#, Wu, S., Huang, P., Chen, M., Zeng, J., Guo, P., Qin, J., Chen, C., Liu, J., Liu, B., He, X., Sun, L.*, Zhang, H.*, Li, L.*, & Pan, T*. (2025). The RNA-binding protein RBM39 scaffolds an m⁶A-dependent RNA decay complex that destabilizes Tat transcripts and restricts HIV-1 reactivation. PLoS biology, 23(11), e3003486. https://doi.org/10.1371/journal.pbio.3003486
  2. Yang, T.#, Chen, M.#, Zhou, M.#, Deng, X., Huang, P., Xie, S., Zeng, J., Luo, J., Zhang, Y., Ma, X., Sun, L., Liu, J., Zhang, H., Li, L.*, Liu, B.*, Qin, J.*, & Pan, T*. (2025). The crosstalk between ubiquitination and GlcNAcylation of CHAF1A regulates HIV-1 latency and reactivation. Journal of virology, 99(12), e0151825. https://doi.org/10.1128/jvi.01518-25
  3. Yu, K.#, Liu, H.#, & Pan, T*. (2025). HIV-1 Tat: Molecular Switch in Viral Persistence and Emerging Technologies for Functional Cure. International journal of molecular sciences, 26(13), 6311. https://doi.org/10.3390/ijms26136311
  4. Chen, C., Zhong, Z., Zhang, W., Xia, B., Wu, L., Liang, L., Zhang, Y., Zhang, H., Zhang, X., Pan, T*, Li, L.*, & Liu, B*. (2025). Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation. Journal of virology, 99(1), e0117324. https://doi.org/10.1128/jvi.01173-24
  5. Xie, S.#, Song, Z.#, Chen, R.#, Zhang, X.#, Wu, S., Chen, J., Huang, P., Liu, H., Yu, K., Zhang, Y., Tan, S., Liu, J., Ma, X., Zhang, H., He, X., & Pan, T*. (2024). The SARS-unique domain (SUD) of SARS-CoV-2 nsp3 protein inhibits the antiviral immune responses through the NF-κB pathway. Journal of medical virology, 96(10), e70007. https://doi.org/10.1002/jmv.70007
  6. Yu, F.#, Liu, X.#, Ou, H.#, Li, X., Liu, R., Lv, X., Xiao, S., Hu, M., Liang, T., Chen, T., Wei, X., Zhang, Z., Liu, S., Liu, H., Zhu, Y., Liu, G., Tu, T., Li, P., Zhang, H.*, Pan, T.*, Ma, X*. (2024). The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2. mBio, 15(8), e0108824. https://doi.org/10.1128/mbio.01088-24
  7. Chen, R., Zhang, X., Yuan, Y., Deng, X., Wu, B., Xi, Z., Wang, G., Lin, Y., Li, R., Wang, X., Zou, F., Liang, L., Yan, H., Liang, C., Li, Y., Wu, S., Deng, J., Zhou, M., Zhang, X., Li, C., Bu, X., Peng, Y., Ke, C., Deng, K., He, X., Zhang, Y., Zhang, Z., Pan, T.*, Zhang, H*. (2022). Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. Advanced science (Weinh), 9(11), e2105378. https://doi.org/10.1002/advs.202105378
  8. Peng, Z., Zhang, Y., Ma, X., Zhou, M., Wu, S., Song, Z., Yuan, Y., Chen, Y., Li, Y., Wang, G., Huang, F., Qiao, Y., Xia, B., Liu, W., Liu, J., Zhang, X., He, X., Pan, T*, Xu, H.*, & Zhang, H*. (2021). Brd4 Regulates the Homeostasis of CD8+ T-Lymphocytes and Their Proliferation in Response to Antigen Stimulation. Frontiers in immunology, 12, 728082. https://doi.org/10.3389/fimmu.2021.728082
  9. Liu, B., Zhang, W., Xia, B., Jing, S., Du, Y., Zou, F., Li, R., Lu, L., Chen, S., Li, Y., Hu, Q., Lin, Y., Zhang, Y., He, Z., Zhang, X., Chen, X., Peng, T., Tang, X., Cai, W., Pan, T*, Li, L.*, Zhang, H*. (2021). Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. The Journal of clinical investigation, 131(19), e150211. https://doi.org/10.1172/JCI150211
  10. Pan, T.#, Chen, R.#, He, X.#, Yuan, Y.#, Deng, X., Li, R., Yan, H., Yan, S., Liu, J., Zhang, Y., Zhang, X., Yu, F., Zhou, M., Ke, C., Ma, X.*, & Zhang, H*. (2021). Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal transduction and targeted therapy, 6(1), 420. https://doi.org/10.1038/s41392-021-00848-1
  11. Pan, T#., Hu, Z.#, Hu, F.#, Zhang, Y.#, Liu, B., Ke, C., She, Q., He, X.*, Tang, X.*, & Zhang, H*. (2021). Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. Cellular & molecular immunology, 18(11), 2560–2562. https://doi.org/10.1038/s41423-021-00776-8

注:#为共同一作，*为共同通讯